Clinical Trials Logo

Wilson Disease clinical trials

View clinical trials related to Wilson Disease.

Filter by:

NCT ID: NCT01980433 Completed - Movement Disorders Clinical Trials

Inhibitory rTMS in Dystonic Wilson Patients

WILSTIM
Start date: January 2014
Phase: N/A
Study type: Interventional

Wilson disease is a genetic disorder resulting in copper accumulation in liver, brain and eye. The neurologic complications include dystonic syndrome, which is a prolonged and excessive muscle activation responsible for abnormal postures. Hand dystonia prevents daily life activities such as writing, which is particularly disabling, since writing is the only mean of communication in these patients with significant slurred speech. Treatment is limited and only partially effective. Low frequency (<or=1Hz) repetitive transcranial magnetic stimulation (rTMS) has shown inhibiting properties when applied over the cortex. Since dystonia has been correlated to hyperactivation of the neurons of the somatosensory cortex (SSC), we hypothesize that one single 20-minute session of 1 Hz rTMS applied on left SSC will improve writing of the right dystonic hand, assessed immediately at the end of the session.

NCT ID: NCT01472874 Completed - Wilson Disease Clinical Trials

Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease

Start date: January 2010
Phase: N/A
Study type: Interventional

Hypothesis: The investigators postulate that patients with Wilson disease who are asymptomatic or who have been effectively treated for their symptoms and are in a maintenance phase therapy can be safely and effectively treated with a single daily dosage of the chelating agent trientine. Specific Aims: To demonstrate that a single daily treatment with trientine is as effective or better than a patient's current maintenance therapy. This will be accomplished by performance of a case control prospective study of patients on their prior therapy, and during a period of treatment with a single weight based dose regimen of trientine. The primary endpoint for this study is the demonstration of equivalence to a patient's prior therapy. Secondary endpoints include: 1) demonstration of stability or improvement in parameters of copper metabolism; 2) improvement in adherence to therapy; 3) no progression of liver disease (defined by changes in synthetic function, albumin and INR, and fibrosis by Fibrotest).

NCT ID: NCT00004339 Completed - Wilson Disease Clinical Trials

Study of Tetrathiomolybdate in Patients With Wilson Disease

Start date: January 1994
Phase: Phase 3
Study type: Interventional

OBJECTIVES: Evaluate the safety and efficacy of ammonium tetrathiomolybdate alone and compared with trientine therapy as initial treatment in patients with Wilson disease presenting neurologically.

NCT ID: NCT00004338 Completed - Wilson Disease Clinical Trials

Study of Zinc for Wilson Disease

Start date: October 1993
Phase: Phase 4
Study type: Interventional

OBJECTIVES: I. Establish the safety and efficacy of extended maintenance zinc therapy in 200 patients with Wilson disease. II. Establish further the role of zinc in the prophylactic treatment of presymptomatic patients by increasing the current cohort from 80 to at least 100 patients. III. Establish further the role of zinc therapy in pregnant patients with Wilson disease. IV. Establish further the role of zinc therapy in children with Wilson disease.